GRFS vs. STVN: Which Stock Should Value Investors Buy Now?

Core Viewpoint - Investors in the Medical - Drugs sector should consider Grifols (GRFS) and Stevanato Group (STVN) for potential value opportunities, with GRFS currently appearing to offer better value based on various metrics [1]. Valuation Metrics - Grifols has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to Stevanato Group, which has a Zacks Rank of 3 (Hold) [3]. - GRFS has a forward P/E ratio of 9.26, significantly lower than STVN's forward P/E of 41.82, suggesting GRFS may be undervalued [5]. - The PEG ratio for GRFS is 0.32, while STVN's PEG ratio is 2.38, indicating that GRFS has a better valuation relative to its expected earnings growth [5]. - GRFS's P/B ratio is 0.76, compared to STVN's P/B of 4.65, further supporting the notion that GRFS is more attractively valued [6]. Conclusion - Overall, GRFS exhibits stronger estimate revision activity and more appealing valuation metrics than STVN, leading to the conclusion that GRFS is the superior option for value investors at this time [7].